A third anti-amyloid, aducanumab (Aduhelm), was fast-tracked for approval in 2021, but the drugmaker took it off the market in early 2024 to focus on other drugs for Alzheimer’s.

A team of scientists including UCL researchers has tested four anti-amyloid Alzheimer's therapeutics to find out how the drugs bind to toxic amyloid beta protein to tackle the disease. Using new ...

When you look at the brain of someone with Alzheimer’s under a microscope, it requires two proteins — beta-amyloid and tau protein, which is thought to occur after amyloid, says Dr. Younes.

The next drug to be approved was lecanemab, which also targets amyloid beta. It received accelerated approval in January 2023; later that year, it received a regular approval, which paved the way ...

There is no ‘amyloid cabal’ in Alzheimer’s research. The scientific conference that had brought us to San Francisco became a lecanemab lovefest — a victory lap for Selkoe and his allies.

Aducanumab vs. Lecanemab. ... Aduhelm targets a key sign of Alzheimer’s disease: plaques of a protein called amyloid-beta, which builds up in the brain and can lead to the death of brain cells.

An illustration depicts cells in an Alzheimer’s-affected brain, with abnormal levels of beta amyloid protein clumping together to form plaques that collect between neurons and disrupt cell function.

Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/- knock-out mice. J Neurosci. 2003 Sep 17;23(24):8532-8. PubMed. Baligács N, Albertini G, Borrie SC, Serneels L, Pridans C ...

Leqembi and Kisunla don’t just reduce amyloid plaques that are implicated in Alzheimer’s disease. According to new research, the drugs boost levels of a healthy form of amyloid beta (Aβ42 ...

A team of scientists including UCL researchers has tested four anti-amyloid Alzheimer's therapeutics to find out how the drugs bind to toxic amyloid beta protein to tackle the disease. Using new ...